Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2052150

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2052150

Compounding Pharmacies Market Insights, Competitive Landscape, and Market Forecast - 2033

PUBLISHED:
PAGES: 184 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
Unprintable PDF & Excel (Multi User License upto 5 users)
USD 8495
Printable PDF & Excel (Enterprise License above 5 users)
USD 10600

Add to Cart

Description

Table of Contents

The compounding pharmacies market is experiencing steady growth due to increasing demand for personalized medications, rising prevalence of chronic diseases, and growing need for customized drug formulations. Compounding pharmacies play a crucial role in preparing patient-specific medications tailored to unique dosage requirements, allergies, and administration preferences. The Compounding Pharmacies Market is expected to reach US$15.4 Bn in 2026 and US$22 Bn by 2033, growing at a CAGR of 5.20% during the forecast period.

Market Insights:

The industry is witnessing significant transformation driven by advancements in pharmaceutical compounding technologies and increasing emphasis on personalized healthcare solutions. Compounding pharmacies are gaining popularity for offering customized medications that are not commercially available in standard formulations. Growing demand for bioidentical hormone replacement therapy, pediatric formulations, and specialty dermatological medications is contributing to market expansion. Additionally, the increasing use of compounding services in veterinary medicine and pain management therapies is strengthening overall market growth. Technological improvements in sterile compounding systems and quality assurance processes are also enhancing operational efficiency and patient safety.

Drivers:

Key drivers of the compounding pharmacies market include the rising prevalence of chronic illnesses, increasing geriatric population, and growing demand for patient-centric treatment approaches. Many patients require personalized medication dosages or allergen-free formulations that are unavailable through mass-produced pharmaceuticals, encouraging the use of compounding pharmacies. Increasing awareness regarding hormone replacement therapies and specialty medications is further supporting market demand. In addition, shortages of commercially manufactured drugs and growing physician preference for customized treatment solutions are accelerating market adoption. Regulatory support for pharmaceutical compounding practices in several countries is also contributing to industry development.

Business Opportunity:

The market presents strong business opportunities for pharmacies and pharmaceutical service providers focusing on customized medicine production, sterile compounding technologies, and specialty therapeutic solutions. Expansion of telehealth services and online prescription management systems is creating new opportunities for remote compounding pharmacy services. Emerging economies are offering lucrative growth prospects due to improving healthcare infrastructure and increasing awareness of personalized medicine. Strategic partnerships between healthcare providers, specialty clinics, and compounding pharmacies are expected to enhance service accessibility and accelerate market expansion. Furthermore, innovation in flavoring technologies, dosage customization, and veterinary compounding solutions is expected to create additional revenue streams.

Region Analysis:

North America dominates the compounding pharmacies market due to advanced healthcare infrastructure, strong presence of specialized pharmacies, and growing adoption of personalized medicine. The region benefits from increasing demand for hormone replacement therapies, pain management medications, and customized pediatric formulations. Europe holds a substantial market share supported by rising healthcare expenditure and growing focus on patient-specific therapies. The Asia Pacific region is expected to witness considerable growth owing to expanding healthcare access, rising chronic disease burden, and increasing awareness regarding compounded medications in countries such as India, China, and Japan. Latin America and the Middle East & Africa are gradually emerging as promising markets due to improving pharmaceutical services and increasing investment in healthcare infrastructure.

Key Players:

  • Walgreen Co.
  • JL Diekman and AQ Touchard (Fresh Therapeutics Compounding Pharmacy)
  • Fagron
  • Albertsons Companies
  • The London Specialist Pharmacy Ltd (Specialist Pharmacy)
  • Galenic Laboratories Limited (Roseway Labs)
  • Aurora Compounding
  • MEDS Pharmacy
  • Apollo Clinical Pharmacy
  • Formul8

Segmentation:

By Dosage Form:

  • Oral
  • Topical
  • Parenteral
  • Rectal
  • Others

By Patient Group:

  • Pediatric
  • Geriatric
  • Adult
  • Veterinary

By Therapeutic Area:

  • Pain management
  • Hormone replacement therapy (BHRT)
  • Dermatology
  • Gastroenterology
  • Others

By Sterility:

  • Sterile
  • Non-Sterile

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Compounding Pharmacies Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global Compounding Pharmacies Market Outlook, 2020 - 2033

  • 3.1. Global Compounding Pharmacies Market Outlook, by Dosage Form, Value (US$ Bn), 2020-2033
    • 3.1.1. Oral
    • 3.1.2. Topical
    • 3.1.3. Parenteral
    • 3.1.4. Rectal
    • 3.1.5. Others
  • 3.2. Global Compounding Pharmacies Market Outlook, by Patient Group, Value (US$ Bn), 2020-2033
    • 3.2.1. Pediatric
    • 3.2.2. Geriatric
    • 3.2.3. Adult
    • 3.2.4. Veterinary
  • 3.3. Global Compounding Pharmacies Market Outlook, by Therapeutic Area, Value (US$ Bn), 2020-2033
    • 3.3.1. Pain management
    • 3.3.2. Hormone replacement therapy (BHRT)
    • 3.3.3. Dermatology
    • 3.3.4. Gastroenterology
    • 3.3.5. Others
  • 3.4. Global Compounding Pharmacies Market Outlook, by Sterility, Value (US$ Bn), 2020-2033
    • 3.4.1. Sterile
    • 3.4.2. Non-Sterile
  • 3.5. Global Compounding Pharmacies Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.5.1. North America
    • 3.5.2. Europe
    • 3.5.3. Asia Pacific
    • 3.5.4. Latin America
    • 3.5.5. Middle East & Africa

4. North America Compounding Pharmacies Market Outlook, 2020 - 2033

  • 4.1. North America Compounding Pharmacies Market Outlook, by Dosage Form, Value (US$ Bn), 2020-2033
    • 4.1.1. Oral
    • 4.1.2. Topical
    • 4.1.3. Parenteral
    • 4.1.4. Rectal
    • 4.1.5. Others
  • 4.2. North America Compounding Pharmacies Market Outlook, by Patient Group, Value (US$ Bn), 2020-2033
    • 4.2.1. Pediatric
    • 4.2.2. Geriatric
    • 4.2.3. Adult
    • 4.2.4. Veterinary
  • 4.3. North America Compounding Pharmacies Market Outlook, by Therapeutic Area, Value (US$ Bn), 2020-2033
    • 4.3.1. Pain management
    • 4.3.2. Hormone replacement therapy (BHRT)
    • 4.3.3. Dermatology
    • 4.3.4. Gastroenterology
    • 4.3.5. Others
  • 4.4. North America Compounding Pharmacies Market Outlook, by Sterility, Value (US$ Bn), 2020-2033
    • 4.4.1. Sterile
    • 4.4.2. Non-Sterile
  • 4.5. North America Compounding Pharmacies Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.5.1. U.S. Compounding Pharmacies Market Outlook, by Dosage Form, 2020-2033
    • 4.5.2. U.S. Compounding Pharmacies Market Outlook, by Patient Group, 2020-2033
    • 4.5.3. U.S. Compounding Pharmacies Market Outlook, by Therapeutic Area, 2020-2033
    • 4.5.4. U.S. Compounding Pharmacies Market Outlook, by Sterility, 2020-2033
    • 4.5.5. Canada Compounding Pharmacies Market Outlook, by Dosage Form, 2020-2033
    • 4.5.6. Canada Compounding Pharmacies Market Outlook, by Patient Group, 2020-2033
    • 4.5.7. Canada Compounding Pharmacies Market Outlook, by Therapeutic Area, 2020-2033
    • 4.5.8. Canada Compounding Pharmacies Market Outlook, by Sterility, 2020-2033
  • 4.6. BPS Analysis/Market Attractiveness Analysis

5. Europe Compounding Pharmacies Market Outlook, 2020 - 2033

  • 5.1. Europe Compounding Pharmacies Market Outlook, by Dosage Form, Value (US$ Bn), 2020-2033
    • 5.1.1. Oral
    • 5.1.2. Topical
    • 5.1.3. Parenteral
    • 5.1.4. Rectal
    • 5.1.5. Others
  • 5.2. Europe Compounding Pharmacies Market Outlook, by Patient Group, Value (US$ Bn), 2020-2033
    • 5.2.1. Pediatric
    • 5.2.2. Geriatric
    • 5.2.3. Adult
    • 5.2.4. Veterinary
  • 5.3. Europe Compounding Pharmacies Market Outlook, by Therapeutic Area, Value (US$ Bn), 2020-2033
    • 5.3.1. Pain management
    • 5.3.2. Hormone replacement therapy (BHRT)
    • 5.3.3. Dermatology
    • 5.3.4. Gastroenterology
    • 5.3.5. Others
  • 5.4. Europe Compounding Pharmacies Market Outlook, by Sterility, Value (US$ Bn), 2020-2033
    • 5.4.1. Sterile
    • 5.4.2. Non-Sterile
  • 5.5. Europe Compounding Pharmacies Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.5.1. Germany Compounding Pharmacies Market Outlook, by Dosage Form, 2020-2033
    • 5.5.2. Germany Compounding Pharmacies Market Outlook, by Patient Group, 2020-2033
    • 5.5.3. Germany Compounding Pharmacies Market Outlook, by Therapeutic Area, 2020-2033
    • 5.5.4. Germany Compounding Pharmacies Market Outlook, by Sterility, 2020-2033
    • 5.5.5. Italy Compounding Pharmacies Market Outlook, by Dosage Form, 2020-2033
    • 5.5.6. Italy Compounding Pharmacies Market Outlook, by Patient Group, 2020-2033
    • 5.5.7. Italy Compounding Pharmacies Market Outlook, by Therapeutic Area, 2020-2033
    • 5.5.8. Italy Compounding Pharmacies Market Outlook, by Sterility, 2020-2033
    • 5.5.9. France Compounding Pharmacies Market Outlook, by Dosage Form, 2020-2033
    • 5.5.10. France Compounding Pharmacies Market Outlook, by Patient Group, 2020-2033
    • 5.5.11. France Compounding Pharmacies Market Outlook, by Therapeutic Area, 2020-2033
    • 5.5.12. France Compounding Pharmacies Market Outlook, by Sterility, 2020-2033
    • 5.5.13. U.K. Compounding Pharmacies Market Outlook, by Dosage Form, 2020-2033
    • 5.5.14. U.K. Compounding Pharmacies Market Outlook, by Patient Group, 2020-2033
    • 5.5.15. U.K. Compounding Pharmacies Market Outlook, by Therapeutic Area, 2020-2033
    • 5.5.16. U.K. Compounding Pharmacies Market Outlook, by Sterility, 2020-2033
    • 5.5.17. Spain Compounding Pharmacies Market Outlook, by Dosage Form, 2020-2033
    • 5.5.18. Spain Compounding Pharmacies Market Outlook, by Patient Group, 2020-2033
    • 5.5.19. Spain Compounding Pharmacies Market Outlook, by Therapeutic Area, 2020-2033
    • 5.5.20. Spain Compounding Pharmacies Market Outlook, by Sterility, 2020-2033
    • 5.5.21. Russia Compounding Pharmacies Market Outlook, by Dosage Form, 2020-2033
    • 5.5.22. Russia Compounding Pharmacies Market Outlook, by Patient Group, 2020-2033
    • 5.5.23. Russia Compounding Pharmacies Market Outlook, by Therapeutic Area, 2020-2033
    • 5.5.24. Russia Compounding Pharmacies Market Outlook, by Sterility, 2020-2033
    • 5.5.25. Rest of Europe Compounding Pharmacies Market Outlook, by Dosage Form, 2020-2033
    • 5.5.26. Rest of Europe Compounding Pharmacies Market Outlook, by Patient Group, 2020-2033
    • 5.5.27. Rest of Europe Compounding Pharmacies Market Outlook, by Therapeutic Area, 2020-2033
    • 5.5.28. Rest of Europe Compounding Pharmacies Market Outlook, by Sterility, 2020-2033
  • 5.6. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Compounding Pharmacies Market Outlook, 2020 - 2033

  • 6.1. Asia Pacific Compounding Pharmacies Market Outlook, by Dosage Form, Value (US$ Bn), 2020-2033
    • 6.1.1. Oral
    • 6.1.2. Topical
    • 6.1.3. Parenteral
    • 6.1.4. Rectal
    • 6.1.5. Others
  • 6.2. Asia Pacific Compounding Pharmacies Market Outlook, by Patient Group, Value (US$ Bn), 2020-2033
    • 6.2.1. Pediatric
    • 6.2.2. Geriatric
    • 6.2.3. Adult
    • 6.2.4. Veterinary
  • 6.3. Asia Pacific Compounding Pharmacies Market Outlook, by Therapeutic Area, Value (US$ Bn), 2020-2033
    • 6.3.1. Pain management
    • 6.3.2. Hormone replacement therapy (BHRT)
    • 6.3.3. Dermatology
    • 6.3.4. Gastroenterology
    • 6.3.5. Others
  • 6.4. Asia Pacific Compounding Pharmacies Market Outlook, by Sterility, Value (US$ Bn), 2020-2033
    • 6.4.1. Sterile
    • 6.4.2. Non-Sterile
  • 6.5. Asia Pacific Compounding Pharmacies Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.5.1. China Compounding Pharmacies Market Outlook, by Dosage Form, 2020-2033
    • 6.5.2. China Compounding Pharmacies Market Outlook, by Patient Group, 2020-2033
    • 6.5.3. China Compounding Pharmacies Market Outlook, by Therapeutic Area, 2020-2033
    • 6.5.4. China Compounding Pharmacies Market Outlook, by Sterility, 2020-2033
    • 6.5.5. Japan Compounding Pharmacies Market Outlook, by Dosage Form, 2020-2033
    • 6.5.6. Japan Compounding Pharmacies Market Outlook, by Patient Group, 2020-2033
    • 6.5.7. Japan Compounding Pharmacies Market Outlook, by Therapeutic Area, 2020-2033
    • 6.5.8. Japan Compounding Pharmacies Market Outlook, by Sterility, 2020-2033
    • 6.5.9. South Korea Compounding Pharmacies Market Outlook, by Dosage Form, 2020-2033
    • 6.5.10. South Korea Compounding Pharmacies Market Outlook, by Patient Group, 2020-2033
    • 6.5.11. South Korea Compounding Pharmacies Market Outlook, by Therapeutic Area, 2020-2033
    • 6.5.12. South Korea Compounding Pharmacies Market Outlook, by Sterility, 2020-2033
    • 6.5.13. India Compounding Pharmacies Market Outlook, by Dosage Form, 2020-2033
    • 6.5.14. India Compounding Pharmacies Market Outlook, by Patient Group, 2020-2033
    • 6.5.15. India Compounding Pharmacies Market Outlook, by Therapeutic Area, 2020-2033
    • 6.5.16. India Compounding Pharmacies Market Outlook, by Sterility, 2020-2033
    • 6.5.17. Southeast Asia Compounding Pharmacies Market Outlook, by Dosage Form, 2020-2033
    • 6.5.18. Southeast Asia Compounding Pharmacies Market Outlook, by Patient Group, 2020-2033
    • 6.5.19. Southeast Asia Compounding Pharmacies Market Outlook, by Therapeutic Area, 2020-2033
    • 6.5.20. Southeast Asia Compounding Pharmacies Market Outlook, by Sterility, 2020-2033
    • 6.5.21. Rest of SAO Compounding Pharmacies Market Outlook, by Dosage Form, 2020-2033
    • 6.5.22. Rest of SAO Compounding Pharmacies Market Outlook, by Patient Group, 2020-2033
    • 6.5.23. Rest of SAO Compounding Pharmacies Market Outlook, by Therapeutic Area, 2020-2033
    • 6.5.24. Rest of SAO Compounding Pharmacies Market Outlook, by Sterility, 2020-2033
  • 6.6. BPS Analysis/Market Attractiveness Analysis

7. Latin America Compounding Pharmacies Market Outlook, 2020 - 2033

  • 7.1. Latin America Compounding Pharmacies Market Outlook, by Dosage Form, Value (US$ Bn), 2020-2033
    • 7.1.1. Oral
    • 7.1.2. Topical
    • 7.1.3. Parenteral
    • 7.1.4. Rectal
    • 7.1.5. Others
  • 7.2. Latin America Compounding Pharmacies Market Outlook, by Patient Group, Value (US$ Bn), 2020-2033
    • 7.2.1. Pediatric
    • 7.2.2. Geriatric
    • 7.2.3. Adult
    • 7.2.4. Veterinary
  • 7.3. Latin America Compounding Pharmacies Market Outlook, by Therapeutic Area, Value (US$ Bn), 2020-2033
    • 7.3.1. Pain management
    • 7.3.2. Hormone replacement therapy (BHRT)
    • 7.3.3. Dermatology
    • 7.3.4. Gastroenterology
    • 7.3.5. Others
  • 7.4. Latin America Compounding Pharmacies Market Outlook, by Sterility, Value (US$ Bn), 2020-2033
    • 7.4.1. Sterile
    • 7.4.2. Non-Sterile
  • 7.5. Latin America Compounding Pharmacies Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.5.1. Brazil Compounding Pharmacies Market Outlook, by Dosage Form, 2020-2033
    • 7.5.2. Brazil Compounding Pharmacies Market Outlook, by Patient Group, 2020-2033
    • 7.5.3. Brazil Compounding Pharmacies Market Outlook, by Therapeutic Area, 2020-2033
    • 7.5.4. Brazil Compounding Pharmacies Market Outlook, by Sterility, 2020-2033
    • 7.5.5. Mexico Compounding Pharmacies Market Outlook, by Dosage Form, 2020-2033
    • 7.5.6. Mexico Compounding Pharmacies Market Outlook, by Patient Group, 2020-2033
    • 7.5.7. Mexico Compounding Pharmacies Market Outlook, by Therapeutic Area, 2020-2033
    • 7.5.8. Mexico Compounding Pharmacies Market Outlook, by Sterility, 2020-2033
    • 7.5.9. Argentina Compounding Pharmacies Market Outlook, by Dosage Form, 2020-2033
    • 7.5.10. Argentina Compounding Pharmacies Market Outlook, by Patient Group, 2020-2033
    • 7.5.11. Argentina Compounding Pharmacies Market Outlook, by Therapeutic Area, 2020-2033
    • 7.5.12. Argentina Compounding Pharmacies Market Outlook, by Sterility, 2020-2033
    • 7.5.13. Rest of LATAM Compounding Pharmacies Market Outlook, by Dosage Form, 2020-2033
    • 7.5.14. Rest of LATAM Compounding Pharmacies Market Outlook, by Patient Group, 2020-2033
    • 7.5.15. Rest of LATAM Compounding Pharmacies Market Outlook, by Therapeutic Area, 2020-2033
    • 7.5.16. Rest of LATAM Compounding Pharmacies Market Outlook, by Sterility, 2020-2033
  • 7.6. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Compounding Pharmacies Market Outlook, 2020 - 2033

  • 8.1. Middle East & Africa Compounding Pharmacies Market Outlook, by Dosage Form, Value (US$ Bn), 2020-2033
    • 8.1.1. Oral
    • 8.1.2. Topical
    • 8.1.3. Parenteral
    • 8.1.4. Rectal
    • 8.1.5. Others
  • 8.2. Middle East & Africa Compounding Pharmacies Market Outlook, by Patient Group, Value (US$ Bn), 2020-2033
    • 8.2.1. Pediatric
    • 8.2.2. Geriatric
    • 8.2.3. Adult
    • 8.2.4. Veterinary
  • 8.3. Middle East & Africa Compounding Pharmacies Market Outlook, by Therapeutic Area, Value (US$ Bn), 2020-2033
    • 8.3.1. Pain management
    • 8.3.2. Hormone replacement therapy (BHRT)
    • 8.3.3. Dermatology
    • 8.3.4. Gastroenterology
    • 8.3.5. Others
  • 8.4. Middle East & Africa Compounding Pharmacies Market Outlook, by Sterility, Value (US$ Bn), 2020-2033
    • 8.4.1. Sterile
    • 8.4.2. Non-Sterile
  • 8.5. Middle East & Africa Compounding Pharmacies Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.5.1. GCC Compounding Pharmacies Market Outlook, by Dosage Form, 2020-2033
    • 8.5.2. GCC Compounding Pharmacies Market Outlook, by Patient Group, 2020-2033
    • 8.5.3. GCC Compounding Pharmacies Market Outlook, by Therapeutic Area, 2020-2033
    • 8.5.4. GCC Compounding Pharmacies Market Outlook, by Sterility, 2020-2033
    • 8.5.5. South Africa Compounding Pharmacies Market Outlook, by Dosage Form, 2020-2033
    • 8.5.6. South Africa Compounding Pharmacies Market Outlook, by Patient Group, 2020-2033
    • 8.5.7. South Africa Compounding Pharmacies Market Outlook, by Therapeutic Area, 2020-2033
    • 8.5.8. South Africa Compounding Pharmacies Market Outlook, by Sterility, 2020-2033
    • 8.5.9. Egypt Compounding Pharmacies Market Outlook, by Dosage Form, 2020-2033
    • 8.5.10. Egypt Compounding Pharmacies Market Outlook, by Patient Group, 2020-2033
    • 8.5.11. Egypt Compounding Pharmacies Market Outlook, by Therapeutic Area, 2020-2033
    • 8.5.12. Egypt Compounding Pharmacies Market Outlook, by Sterility, 2020-2033
    • 8.5.13. Nigeria Compounding Pharmacies Market Outlook, by Dosage Form, 2020-2033
    • 8.5.14. Nigeria Compounding Pharmacies Market Outlook, by Patient Group, 2020-2033
    • 8.5.15. Nigeria Compounding Pharmacies Market Outlook, by Therapeutic Area, 2020-2033
    • 8.5.16. Nigeria Compounding Pharmacies Market Outlook, by Sterility, 2020-2033
    • 8.5.17. Rest of Middle East Compounding Pharmacies Market Outlook, by Dosage Form, 2020-2033
    • 8.5.18. Rest of Middle East Compounding Pharmacies Market Outlook, by Patient Group, 2020-2033
    • 8.5.19. Rest of Middle East Compounding Pharmacies Market Outlook, by Therapeutic Area, 2020-2033
    • 8.5.20. Rest of Middle East Compounding Pharmacies Market Outlook, by Sterility, 2020-2033
  • 8.6. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Walgreen Co.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. JL Diekman and AQ Touchard (Fresh Therapeutics Compounding Pharmacy)
    • 9.4.3. Fagron
    • 9.4.4. Albertsons Companies
    • 9.4.5. The London Specialist Pharmacy Ltd (Specialist Pharmacy)
    • 9.4.6. Galenic Laboratories Limited (Roseway Labs)
    • 9.4.7. Aurora Compounding
    • 9.4.8. MEDS Pharmacy
    • 9.4.9. Apollo Clinical Pharmacy
    • 9.4.10. Formul8

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!